TY  - JOUR
A1  - Projahn, Delia
A1  - Simsekyilmaz, Sakine
A1  - Singh, Smriti
A1  - Kanzler, Isabella
A1  - Kramp, Birgit K.
A1  - Langer, Marcella
A1  - Burlacu, Alexandrina
A1  - Bernhagen, Jürgen
A1  - Klee, Doris
A1  - Zernecke, Alma
A1  - Hackeng, Tilman M.
A1  - Groll, Jürgen
A1  - Weber, Christian
A1  - Liehn, Elisa A.
A1  - Koenen, Roy R.
T1  - Controlled intramyocardial release of engineered chemokines by biodegradable hydrogels as a treatment approach of myocardial infarction
JF  - Journal of Cellular and Molecular Medicine
N2  - Myocardial infarction (MI) induces a complex inflammatory immune response, followed by the remodelling of the heart muscle and scar formation. The rapid regeneration of the blood vessel network system by the attraction of hematopoietic stem cells is beneficial for heart function. Despite the important role of chemokines in these processes, their use in clinical practice has so far been limited by their limited availability over a long time-span in vivo. Here, a method is presented to increase physiological availability of chemokines at the site of injury over a defined time-span and simultaneously control their release using biodegradable hydrogels. Two different biodegradable hydrogels were implemented, a fast degradable hydrogel (FDH) for delivering Met-CCL5 over 24hrs and a slow degradable hydrogel (SDH) for a gradual release of protease-resistant CXCL12 (S4V) over 4weeks. We demonstrate that the time-controlled release using Met-CCL5-FDH and CXCL12 (S4V)-SDH suppressed initial neutrophil infiltration, promoted neovascularization and reduced apoptosis in the infarcted myocardium. Thus, we were able to significantly preserve the cardiac function after MI. This study demonstrates that time-controlled, biopolymer-mediated delivery of chemokines represents a novel and feasible strategy to support the endogenous reparatory mechanisms after MI and may compliment cell-based therapies.
KW  - chemokines
KW  - therapy
KW  - cardiovascular pharmacology
KW  - remodelling
KW  - endothelial progenitor cells
KW  - left-ventricular function
KW  - heart-failure
KW  - rat model
KW  - recruitment
KW  - factor-I
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-116597
SN  - 1582-4934
VL  - 18
IS  - 5
ER  - 
TY  - JOUR
A1  - Chubanov, Vladimir
A1  - Ferioli, Silvia
A1  - Wisnowsky, Annika
A1  - Simmons, David G.
A1  - Leitzinger, Christin
A1  - Einer, Claudia
A1  - Jonas, Wenke
A1  - Shymkiv, Yuriy
A1  - Gudermann, Thomas
A1  - Bartsch, Harald
A1  - Braun, Attila
A1  - Akdogan, Banu
A1  - Mittermeier, Lorenz
A1  - Sytik, Ludmila
A1  - Torben, Friedrich
A1  - Jurinovic, Vindi
A1  - van der Vorst, Emiel P. C.
A1  - Weber, Christian
A1  - Yildirim, Önder A.
A1  - Sotlar, Karl
A1  - Schürmann, Annette
A1  - Zierler, Susanna
A1  - Zischka, Hans
A1  - Ryazanov, Alexey G.
T1  - Epithelial magnesium transport by TRPM6 is essential for prenatal development and adult survival
JF  - eLife
N2  - Mg2+ regulates many physiological processes and signalling pathways. However, little is known about the mechanisms underlying the organismal balance of Mg2+. Capitalizing on a set of newly generated mouse models, we provide an integrated mechanistic model of the regulation of organismal Mg2+ balance during prenatal development and in adult mice by the ion channel TRPM6. We show that TRPM6 activity in the placenta and yolk sac is essential for embryonic development. In adult mice, TRPM6 is required in the intestine to maintain organismal Mg2+ balance, but is dispensable in the kidney. Trpm6 inactivation in adult mice leads to a shortened lifespan, growth deficit and metabolic alterations indicative of impaired energy balance. Dietary Mg2+ supplementation not only rescues all phenotypes displayed by Trpm6-deficient adult mice, but also may extend the lifespan of wildtype mice. Hence, maintenance of organismal Mg2+ balance by TRPM6 is crucial for prenatal development and survival to adulthood.
KW  - signalling pathways
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-164987
VL  - 5
ER  - 
TY  - JOUR
A1  - Butt, Elke
A1  - Stempfle, Katrin
A1  - Lister, Lorenz
A1  - Wolf, Felix
A1  - Kraft, Marcella
A1  - Herrmann, Andreas B.
A1  - Viciano, Cristina Perpina
A1  - Weber, Christian
A1  - Hochhaus, Andreas
A1  - Ernst, Thomas
A1  - Hoffmann, Carsten
A1  - Zernecke, Alma
A1  - Frietsch, Jochen J.
T1  - Phosphorylation-dependent differences in CXCR4-LASP1-AKT1 interaction between breast cancer and chronic myeloid leukemia
JF  - Cells
N2  - The serine/threonine protein kinase AKT1 is a downstream target of the chemokine receptor 4 (CXCR4), and both proteins play a central role in the modulation of diverse cellular processes, including proliferation and cell survival. While in chronic myeloid leukemia (CML) the CXCR4 is downregulated, thereby promoting the mobilization of progenitor cells into blood, the receptor is highly expressed in breast cancer cells, favoring the migratory capacity of these cells. Recently, the LIM and SH3 domain protein 1 (LASP1) has been described as a novel CXCR4 binding partner and as a promoter of the PI3K/AKT pathway. In this study, we uncovered a direct binding of LASP1, phosphorylated at S146, to both CXCR4 and AKT1, as shown by immunoprecipitation assays, pull-down experiments, and immunohistochemistry data. In contrast, phosphorylation of LASP1 at Y171 abrogated these interactions, suggesting that both LASP1 phospho-forms interact. Finally, findings demonstrating different phosphorylation patterns of LASP1 in breast cancer and chronic myeloid leukemia may have implications for CXCR4 function and tyrosine kinase inhibitor treatment.
KW  - LASP1
KW  - CXCR4
KW  - AKT1
KW  - CML
KW  - breast cancer
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-200638
SN  - 2073-4409
VL  - 9
IS  - 2
ER  -